In this role the MAL will be accountable for leading workstreams that advance clinical practice in alignment with medical and brand strategy with a focus on the Medical and Scientific Affairs missions to deliver world class product launches, healthcare system change and practice changing evidence. The MAL will be accountable for establishing and maintaining AZ’s position as a scientific leader while delivering high level external stakeholder engagement with external experts, professional societies and patient groups.
- To develop and lead the Medical strategy and its execution in the UK for the biologics portfolio across severe asthma and other emerging autoimmune diseases
- To provide Medical input into all UK strategic and operational planning initiatives for the Respiratory and Immunology Business Unit
- To build a strong network with key external stakeholders in the severe asthma and other emerging autoimmune disease (incl. KEEs, payers, patient advocacy groups) to deliver clinical and patient insight, customer focus and clinical governance into commercial objectives
- To develop and deliver pre-launch and peri-launch medical plans and activities
- To lead Field Medical Affairs team (MSLs) to deliver pre- and post-launch medical objectives
- Act to ensure GxP requirements are fully complied with and in line with the local Quality Management System (QMS) SOP and all other AZ policies and Standards